Not Signed In -
Floxuridine |
Fluorodeoxyuridine; FUDR |
Clinical Trial: Intraperitoneal Floxuridine in Gastric Carcinoma
This study is currently recruiting patients.
|
Purpose
Patients undergoing curative resection for gastric cancer have been shown to benefit from postoperative chemotherapy with 5-fluoruracil + leucovorin, and radiation in an Intergroup Study (INT116). However, both local and distal relapses still occur in 50% at 3 years. This study is based on the hypothesis that 2 cycles (of 3 days each 2 weeks apart) of intraperitoneal FUDR (floxuridine), followed by the above treatment will improve outcome.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Stomach Neoplasms | Drug: fluorodeoxyuridine (FUDR) | Phase I Phase II |
MedlinePlus related topics: Stomach Cancer
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study
Expected Total Enrollment: 25
Study start: September 2002
Eligibility
Genders Eligible for Study: Both
Criteria
Location and Contact Information
California
University of Southern California, Los Angeles, California, 90033, United States; Not yet recruiting
Heinz-Josef Lenz, MD 323 865 3055 lenz@hsc.usc.edu
New York
New York University School of Medicine, New York, New York, 10016, United States; Recruiting
Elliot Newman, MD 212 263 7302 elliot.newman@med.nyu.edu
Franco M Muggia, MD, Principal Investigator
More Information
Record last reviewed: April 2003
Last Updated: October 13, 2004
Record first received: April 14, 2003
ClinicalTrials.gov Identifier: NCT00058916
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Floxuridine (Drug Digest)
- Fluorodeoxyuridine (Drug Digest)
email this page
print this page
bookmark this page
feedback on this page
